Contains A Growth Factor Or Growth Regulator Patents (Class 435/405)
-
Publication number: 20130217120Abstract: Disclosed are placenta-derived cell-conditioned culture media for stem cells. An animal-free, feeder-free method using the media is also provided for culturing stem cells. The media can prevent the stem cells from being contaminated with xenogeneic proteins or cells, and maintain human embryonic stem cells in an undifferentiated state for a long period of time in vitro with an economic benefit.Type: ApplicationFiled: April 8, 2013Publication date: August 22, 2013Applicant: Korea University Research and Business FoundationInventor: Korea University Research and Business Foundation
-
Publication number: 20130217129Abstract: Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium.Type: ApplicationFiled: March 15, 2013Publication date: August 22, 2013Applicant: ALLERGAN, INC.Inventor: Allergan, Inc.
-
Publication number: 20130210725Abstract: Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium.Type: ApplicationFiled: March 15, 2013Publication date: August 15, 2013Applicant: Allergan, Inc.Inventor: Allergan, Inc.
-
Publication number: 20130211186Abstract: The present invention relates to the production and culture of undifferentiated spermatogonial stem cells that can be maintained long term and are feeder free. The resultant feeder-free populations can be used in any of a number of protocols including the generation of progeny bulls. The present invention includes novel methods required for the successful enrichment of bovine spermatogonial stem cells, novel cell lines and other components used for the same, as well as the resultant stem cell compositions.Type: ApplicationFiled: February 11, 2013Publication date: August 15, 2013Applicant: WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATIONInventor: WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION
-
Publication number: 20130203169Abstract: Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium.Type: ApplicationFiled: March 15, 2013Publication date: August 8, 2013Applicant: ALLERGAN, INC.Inventor: ALLERGAN, INC.
-
Publication number: 20130195959Abstract: The present disclosure is drawn to compositions and methods of making and using lyophilized platelet lysates. Specifically, a method of preparing a composition suitable for therapeutic use or as a culture medium can comprise steps of concentrating platelets from a platelet source to form a platelet rich portion of the platelet source, and lysing the platelets in the platelet rich portion to form a plurality of lysates. An additional step includes lyophilizing the lysates to form lyophilized platelet lysates in a composition with released concentrations of available growth factors, cytokines, and chemokines. In one example, at 30%, by platelet count, of platelets from a platelet source can be lysed using this process.Type: ApplicationFiled: January 26, 2012Publication date: August 1, 2013Inventor: Amit Patel
-
Publication number: 20130189327Abstract: The invention relates to a liver organoid, uses thereof and method for obtaining them.Type: ApplicationFiled: July 29, 2011Publication date: July 25, 2013Applicant: KONINKIJIKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPENInventors: Meritxell Huch Ortega, Johannes Carolus Clevers
-
Patent number: 8486700Abstract: The invention relates to methods and compositions for the differentiation of stromal cells from adipose tissue into hematopoietic supporting stromal cells and myocytes of both the skeletal and smooth muscle type. The cells produced by the methods are useful in providing a source of fully differentiated and functional cells for research, transplantation and development of tissue engineering products for the treatment of human diseases and traumatic tissue injury repair.Type: GrantFiled: April 12, 2011Date of Patent: July 16, 2013Assignee: Artecel Sciences Inc.Inventors: Jeffrey Martin Gimble, Yuan-Di Chang Halvorsen, William O. Wilkison
-
Publication number: 20130177537Abstract: Disclosed are methods for expanding stem cells that use a unique combination of environmental factors and cell culture conditions to produce stem cells having enhanced proliferation and differentiation characteristics. Also disclosed are methods for enhancing the engraftment and/or migratory potential of stem cells for therapeutic uses. Stem cells having unique proliferation, differentiation, migratory and engraftment characteristics are also disclosed.Type: ApplicationFiled: March 6, 2013Publication date: July 11, 2013Applicant: STEMEDICA CELL TECHNOLOGIES, INC.Inventor: Stemedica Cell Technologies, Inc.
-
Patent number: 8481308Abstract: Methods for culturing undifferentiated mammalian cells, such as stem and progenitor cells, are provided. The methods involve incubating the cell in the presence of a sustained release composition containing at least one growth factor, wherein the sustained release composition continuously releases the growth factor(s), and wherein the presence of the sustained level of growth factor maintains the cell in an undifferentiated state.Type: GrantFiled: July 1, 2011Date of Patent: July 9, 2013Assignee: Regenerative Research FoundationInventors: Jeffrey Stern, Sally Temple Stern
-
Publication number: 20130171110Abstract: Compositions and methods that employ various combinations of such factors as retinoic acid signaling inhibitors, antioxidants, BMP4, VEGF, prostaglandin E2 pathway stimulants, TPO, SCF, FLT-3, EPO, TGF?1, p38 MAPK inhibitors, beta adrenergic receptor agonists, cell cycle inhibitors, RXR agonists, Cripto, and chromatin remodelers to drive differentiation of pluripotent stem cells towards primitive blood cells. Uses of such primitive blood cells are provided.Type: ApplicationFiled: December 5, 2012Publication date: July 4, 2013Applicant: DeWitt Ross & Stevens S.C.Inventor: DeWitt Ross & Stevens S.C.
-
Patent number: 8475788Abstract: The invention is directed to methods of promoting the healing of spinal cord injury. The invention is further directed to methods of minimizing the extent of scarring following spinal cord injury. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents.Type: GrantFiled: November 27, 2007Date of Patent: July 2, 2013Assignee: Stemnion, Inc.Inventors: George L. Sing, Diana L. Clarke, Vivienne S. Marshall
-
Patent number: 8476070Abstract: Well-defined, xeno-free culture media which comprise a TGF-beta isoform or the chimera formed between IL6 and the soluble IL6 receptor (IL6RIL6), which are capable of maintaining stem cells, and particularly, human embryonic stem cells, in an undifferentiated state are provided. Also provided are cell cultures comprising the culture media and the stem cells and methods of expanding and deriving embryonic stem cells in such well-defined, xeno-free culture media. In addition, the present invention provides methods of differentiating ESCs or EBs formed therefrom for the generation of lineage specific cells.Type: GrantFiled: August 29, 2006Date of Patent: July 2, 2013Assignee: Technion Research & Development Foundation LimitedInventors: Michal Amit, Joseph Itskovitz-Eldor
-
Patent number: 8476071Abstract: The present invention relates to methods for expanding a stem cell population. More particularly, the invention relates, inter alia, to methods and compositions for expanding a stem cell population, particularly a hematopoietic stem cell population.Type: GrantFiled: August 9, 2012Date of Patent: July 2, 2013Assignee: Stowers Institute for Medical ResearchInventors: John M. Perry, Linheng Li, Justin C. Grindley
-
Publication number: 20130164849Abstract: The present invention relates to a medium for culturing mesenchymal stem cells, and more particularly to a medium composition for culturing mesenchymal stem cells, which contains basal medium, L-ascorbic acid 2-phosphate, fetal bovine serum, basic fibroblast growth factor (b-FGF), non-essential amino acids (NEAAs), insulin, N-acetyl-L-cysteine, calcium chloride, and hydrocortisone, and a method of culturing mesenchymal stem cells using the same. According to the present invention, a number of mesenchymal stem cells required for stem cell therapy can be obtained in a short time, and the ability of mesenchymal stem cells to differentiate is improved so that they are useful for stem cell therapy.Type: ApplicationFiled: July 18, 2011Publication date: June 27, 2013Applicant: RNL Bio Co., Ltd.Inventors: Jeong Chan Ra, Sung Keun Kang, Ju Yeon Seo, Hyoeun Kim
-
Patent number: 8460929Abstract: Provided are methods and compositions for constructing stable mammalian embryonic epithelial tissues and organs as well as constructing kidney tissue, and treating renal failure. Disclosed are methods of using an active epithelial growth factor having the capability of effectuating induction of growth and morphogenesis is cells.Type: GrantFiled: June 4, 2008Date of Patent: June 11, 2013Assignee: The Regents of the University of CaliforniaInventors: Sanjay Kumar Nigam, Eran Rosines
-
Publication number: 20130130373Abstract: The present disclosure relates, in general to a kit comprising a serum replacement and one or more labile factors, such as growth factors, packaged separately in the kit. It is contemplated that the kit provides advantages to improve cell growth in culture compared to cells cultured not using the kit described herein.Type: ApplicationFiled: November 9, 2012Publication date: May 23, 2013Applicant: ESSENTIAL PHARMACEUTICALS, LLCInventor: Essential Pharmaceuticals, LLC
-
Patent number: 8431399Abstract: The present invention provides a method for restoring native chondrocyte phenotype and functions of, and/or increasing type II collagen as well as aggrecan mRNA expression levels and GAG accumulation level in dedifferentiated chondrocytes which have been subcultured and expanded in vitro, which comprising culturing the said dedifferentiated chondrocytes in vitro with a medium comprising type II collagen, or its biologically active peptide fragment(s) or analogs with or without growth factor(s), wherein the type II collagen or its biologically active peptide fragment(s) or analogs are effective to restore chondrocyte phenotype and functions of, and/or to increase type II collagen and aggrecan expression levels and GAG accumulation level in the said dedifferentiated chondrocytes.Type: GrantFiled: March 2, 2010Date of Patent: April 30, 2013Assignee: Taipei Medical UniversityInventors: Yu-Hui Tsai, Li-Hsuan Chiu, Chin-Chean Wong, Wen-Fu Lai, Shih-Ching Chen
-
Patent number: 8426203Abstract: Previous methods for culturing primate pluripotent stem cells have required either fibroblast feeder cells or a medium which was exposed to fibroblast feeder cells to maintain the stem cells in an undifferentiated state. It has now been found that high levels of fibroblast growth factor in a medium together with at least one of gamma aminobutyric acid, pipecolic acid, and lithium, enables pluripotent stem cells to remain undifferentiated indefinitely through multiple passages, even without feeder cells or conditioned medium. Without beta-mercaptoethanol, the medium improves cloning efficiency. Also, a matrix of human proteins can be used to culture the undifferentiated cells without exposing the cells to animal products. Further disclosed are new primate pluripotent cell lines made using the defined culture conditions, including the medium and the matrix. Such new cell lines will have never been exposed to animal cells, animal products, feeder cells or conditioned medium.Type: GrantFiled: March 22, 2012Date of Patent: April 23, 2013Assignee: Wisconsin Alumni Research FoundationInventors: James A. Thomson, Tenneille Ludwig
-
Patent number: 8415155Abstract: Methods and composition for the production of cardiomyocytes from differentiation of pluripotent stem cells are provided. For example, in certain aspects methods including differentiating pluripotent stem cells in a large volume of suspension culture in the presence of ROCK inhibitors are described. In further aspects, methods for differentiation of stem cells into cardiomyocytes that overcome variability between different stem cell clones and different batch of culture medium are provided.Type: GrantFiled: October 19, 2010Date of Patent: April 9, 2013Assignee: Cellular Dynamics International, Inc.Inventors: Casey Stankewicz, Matt Riley, Nathaniel Beardsley, Wen Bo Wang, Peter Fuhrken, Steven Kattman
-
Patent number: 8415158Abstract: The present invention relates to cell culture methods and compositions that are essentially serum-free and comprise a basal salt nutrient solution and an ErbB3 ligand.Type: GrantFiled: February 29, 2012Date of Patent: April 9, 2013Assignee: ViaCyte, Inc.Inventors: Allan J Robins, Thomas C Schulz
-
Patent number: 8404482Abstract: The present invention is directed to an in vitro method for promoting differentiation and proliferation of human T helper lymphocytes that express IL17 (Th-IL17+ cells). The instant method may be used to generate a population of human T helper lymphocytes that express IL17 (Th-IL17+ cells) in vitro. Methods for screening to identify agents capable of modulating Th-IL17+ cell differentiation are also encompassed by the present invention. Isolated, pure populations of homogeneous Th-IL17+ cells that do not express cellular markers characteristic of Th1, Th2, or Treg cells are also encompassed herein.Type: GrantFiled: May 17, 2012Date of Patent: March 26, 2013Assignee: New York UniversityInventors: Nicolas Manel, Dan R. Littman
-
Publication number: 20130040390Abstract: The present invention provides a chemically defined culture system, by which induced pluripotent stem (iPS) cells are obtained with high efficiency. The culture medium supplement of the present invention includes vitamin C and a glycogen synthase kinase-3 inhibitor; another culture medium supplement of the present invention further includes, in addition to vitamin C and the glycogen synthase kinase-3 inhibitor, vitamin B12, insulin, a receptor tyrosine kinase, and an anti-oxidant; and the culture medium supplement of the present invention may further be a mixture of the above two culture medium supplements with a serum replacement cell growth promoter. The present invention further provides a complete culture medium for iPS cells, which is formed by one or more of a basal culture medium, serum, and a serum replacement supplement, and the above culture medium supplements, or formed only by the above culture medium supplements and a basal culture medium.Type: ApplicationFiled: July 29, 2010Publication date: February 14, 2013Applicant: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCEInventors: Duanqing Pei, Jiekai Chen, Jing Liu
-
Patent number: 8367406Abstract: Pluripotent cells that are immunopositive for both the neural progenitor marker nestin and a pluripotent cell marker are provided. The cells exhibit rapid doubling times and can be maintained in vitro for extended periods. Also provided are cell cultures containing the pluripotent cells, a method of transplanting human pluripotent cells to a host, and a method of reducing seizure activity in a subject. These pluripotent cells, when transplanted into the ventricle of a host animal, migrate to the site of damage and adopt a suitably corrective phenotype, resulting in both structural and functional restoration.Type: GrantFiled: July 20, 2009Date of Patent: February 5, 2013Assignee: Celavie Biosciences, LLCInventor: Oleg V. Kopyov
-
Publication number: 20130029414Abstract: Albumin-supplemented and xenogeneic product-free cell culture media, cell culture media supplements, and cell culture media kits for the support of primary culture of normal non-hematopoietic cells of mesodermal origin suitable for both research and clinical applications.Type: ApplicationFiled: July 29, 2011Publication date: January 31, 2013Inventor: David K. Moscatello
-
Publication number: 20130017604Abstract: Methods and compositions for directing adipose-derived stromal cells cultivated in vitro to differentiate into cells of the chondrocyte lineage are disclosed. The invention further provides a variety of chondroinductive agents which can be used singly or in combination with other nutrient components to induce chondrogenesis in adipose-derived stromal cells either in cultivating monolayers or in a biocompatible lattice or matrix in a three-dimensional configuration. Use of the differentiated chondrocytes for the therapeutic treatment of a number of human conditions and diseases including repair of cartilage in vivo is disclosed.Type: ApplicationFiled: September 30, 2011Publication date: January 17, 2013Applicant: ARTECEL SCIENCES INC.Inventors: Yuan-Di C. Halvorsen, William O. Wilkison, Jeffrey Martin Gimble
-
Publication number: 20120329152Abstract: The present invention relates to methods of induction and isolation of progenitor cells from stem cell cultures, specifically liver progenitor cells from human embryonic stem cell cultures. In one embodiment, the present invention provides a method of inducing hepatocyte-like progenitor cells by placing a quantity of human embryonic stem cells in a medium supplemented with an inhibitor of the MAPK/MEK/ERK signaling pathway, FGFR, GSK3 and/or BMP.Type: ApplicationFiled: August 31, 2012Publication date: December 27, 2012Applicant: UNIVERSITY OF SOUTHERN CALIFORNIAInventors: Martin F. Pera, Tracy Zinberg, Kouichi Hasegawa
-
Patent number: 8338175Abstract: The present disclosure describes a tissue system with conjunctival cells, including conjunctival stem cells. The conjunctival tissue system is derived from isolated tissue comprising conjunctival cells, and is suitable for restoring ocular surface impairments, particularly those that result from damaged or diseased conjunctiva. The tissue system is generated using a simple single medium culture scheme, and a support material, such as human amniotic membrane. The conjunctival tissue system generate is suitable for transplantation to treat the ocular surface of an eye of a subject that is damaged or diseased.Type: GrantFiled: February 23, 2007Date of Patent: December 25, 2012Assignee: Reliance Life Sciences Pvt. Ltd.Inventors: Kashyap Subhadra Devi, Kishore Reddy, Viraf Vasania
-
Patent number: 8337829Abstract: The subject invention pertains to tumor cell lines useful for increasing the proliferation potential of any human or animal cell in culture, thereby providing immortalized or continuous cell lines and cultures. The invention also concerns proliferation factors, and compositions containing the factors, which are capable of increasing the proliferation potential of any human or other animal cell in culture. The subject invention further pertains to a method for proliferating cells in culture by contacting cells with the proliferation factors. The proliferated cells can range in plasticity and can include, for example, blast cells, fertilized ova, non-fertilized gametes, embryonic stem cells, adult stem cells, precursor or progenitor cells, and highly specialized cells. Optionally, the cells can be induced to cease proliferation.Type: GrantFiled: October 6, 2011Date of Patent: December 25, 2012Assignees: University of South Florida, University of ChileInventors: Thomas B. Freeman, Pablo Caviedes, Raul Caviedes
-
Patent number: 8323973Abstract: A cell culture substrate having at least one area for culturing a cell on a substrate, characterized in that the culturing area comprises an area releasably holding a biologically active substance having a biological activity to the cell and an area for immobilizing a biologically active substance having a biological activity to the cell.Type: GrantFiled: December 13, 2004Date of Patent: December 4, 2012Assignee: Canon Kabushiki KaishaInventors: Qsamu Kanome, Kohei Watanabe, Takeshi Miyazaki, Tomoyo Fujiyama, Ryoichi Matsuda
-
Publication number: 20120264190Abstract: Compositions comprising decellularized and delipidized extracellular matrix derived from adipose or loose connective tissue, and therapeutic uses thereof. Methods for treating, repairing or regenerating defective, diseased, or damaged adipose or loose connective tissues or organs in a subject, preferably a human, and/or for tissue engineering, filing soft tissue defects, and cosmetic and reconstructive surgery, using a decellularized and delipidized adipose or loose connective tissue extracellular matrix of the invention are provided. Methods of preparing tissue culture surfaces and culturing cells with adsorbed decellularized and delipidized adipose or loose connective tissue extracellular matrix are also provided.Type: ApplicationFiled: June 6, 2012Publication date: October 18, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Karen L. Christman, D. Adam Young
-
Publication number: 20120264215Abstract: Disclosed are placenta-derived cell-conditioned culture media for stem cells. An animal-free, feeder-free method using the media is also provided for culturing stem cells. The media can prevent the stem cells from being contaminated with xenogeneic proteins or cells, and maintain human embryonic stem cells in an undifferentiated state for a long period of time in vitro with an economic benefit.Type: ApplicationFiled: March 15, 2012Publication date: October 18, 2012Applicant: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUDATION OF KOREA UNIVERSITYInventors: Byung Soo KIM, Seung-Jin LEE, Yong PARK, Ji Hye JUNG, Ji Hye KIM
-
Patent number: 8278105Abstract: The present invention relates to methods of induction and isolation of progenitor cells from stem cell cultures, specifically liver progenitor cells from human embryonic stem cell cultures. In one embodiment, the present invention provides a method of inducing hepatocyte-like progenitor cells by placing a quantity of human embryonic stem cells in a medium supplemented with an inhibitor of the MAPK/MEK/ERK signaling pathway, FGFR, GSK3 and/or BMP.Type: GrantFiled: September 9, 2009Date of Patent: October 2, 2012Assignee: University of Southern CaliforniaInventors: Martin F. Pera, Tracy L. Zinberg, Kouichi Hasegawa
-
Publication number: 20120244567Abstract: Methods of culturing embryonic stem cells in a format suitable for high-throughput screening (HTS) are provided. In addition compounds that show differential cytotoxic/protective activity on embryonic stem cells (ESCs) and neurological stem cells (NSCs) are provided.Type: ApplicationFiled: September 3, 2010Publication date: September 27, 2012Applicant: BUCK INSTITUTE FOR RESEARCH ON AGINGInventor: Xianmin Zeng
-
Publication number: 20120245097Abstract: Disclosed herein is a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues. The synthetic peptide has at least 80% amino acid sequence identity to SEQ ID NO: 1, and includes at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1. Also disclosed herein are compositions containing the synthetic peptide and applications thereof. According to various embodiments of the present disclosure, the synthetic peptide is useful in promoting stem cells proliferation or wound healing.Type: ApplicationFiled: March 23, 2012Publication date: September 27, 2012Inventors: Yeou-Ping Tsao, Tsung-Chuan Ho
-
Publication number: 20120225814Abstract: A medium for growing vascular lineage cells is described. The vascular lineage cell growth medium includes an oligosaccharide-based hydrogel and a growth factor that promotes vascularization by vascular lineage cells.Type: ApplicationFiled: November 10, 2010Publication date: September 6, 2012Applicant: The Johns Hopkins UniversityInventors: Donny Hanjaya-Putra, Sharon Gerecht
-
Publication number: 20120225480Abstract: Provided are serum-free culture media which comprise basic fibroblast growth factor (bFGF), transforming growth factor beta-3, ascorbic acid, xeno-free serum replacement and a lipid mixture. The media may also comprise an IL6R/IL6 chimera, or leukemia inhibitory factor (LIF); wherein the culture medium is capable of maintaining pluripotent stem cells in an undifferentiated state in the absence of feeder cell support. Also provided are cell cultures comprising pluripotent stem cells such as human embryonic stem cells and induced pluripotent stem (iPS) cells, and methods of using the same for expanding pluripotent stem cells in an undifferentiated state using two-dimensional or three-dimensional culture systems. Methods of expanding iPS cells in a suspension culture devoid of substrate adherence and cell encapsulation are also provided.Type: ApplicationFiled: November 11, 2010Publication date: September 6, 2012Applicant: Technion Research & Development Foundatio Ltd.Inventors: Michal Amit, Joseph Itskovitz-Eldor
-
Publication number: 20120219535Abstract: Provided herein is a method to isolate a cranial neural crest stem cell and novel compositions containing the cell. Also provided are compositions and methods to clonally expand the population and differentiate the cells into various phenotypes. Therapeutic methods for the compositions are further provided.Type: ApplicationFiled: August 31, 2010Publication date: August 30, 2012Inventors: Robert E. Maxson, JR., Mamoru Ishii
-
Publication number: 20120220032Abstract: The present invention provides a method of determining the optimal composition of a serum-free, eukaryotic cell culture medium supplement, using 2-level factorial design and the steepest ascent method. The invention further provides a method of making a serum-free eukaryotic cell culture medium supplement and the generated thereof. The invention further provides a method of making a serum-free, eukaryotic cell culture medium and the medium generated thereof. The invention further provides a kit containing the medium of the invention. The invention also provides a method of expanding CD34<+> hematopoietic cells and a composition comprising CD34<+> hematopoietic cells in a serum-free, eukaryotic cell culture medium of the invention.Type: ApplicationFiled: May 10, 2012Publication date: August 30, 2012Applicant: SINO CELL TECHNOLOGIES INC.Inventors: Shiaw-Min Hwang, Chi-Hsien Liu, Chao-Ling Yao, I-Ming Chu, Tzu-Bou Hsieh
-
Patent number: 8252591Abstract: The invention provides tissue culture system for primary cells (e.g. normal mammalian primary epithelial progenitors). This system includes: a) a serum-free, chemically defined cell culture media; and, b) methods for isolation and in vitro long-term propagation of primary cells (e.g. primary epithelial cells). Primary cells so isolated and cultured can be kept undifferentiated and proliferate for many weeks (>15 weeks) or population doubling (>35 PD) without senescence, or any detectable genetic alterations. Upon changing media/culture conditions, these cells can be induced to differentiate. The invention also provides methods to transform normal primary cells so cultured into “cancer stem cells.” The genetically defined cancer stem cell tumor model mimics the behavior of the disease closely, e.g., the cells are invasive, hormone responsive and metastatic when injected into mice. The tumor cells express genes that are specific to cancer stem cells identified in patient samples.Type: GrantFiled: May 6, 2005Date of Patent: August 28, 2012Assignees: Whitehead Institute for Biomedical Research, The Brigham and Women's HospitalInventors: Tan A. Ince, Robert A. Weinberg
-
Publication number: 20120196312Abstract: The invention relates to a method for culturing epithelial stem cells, isolated tissue fragments comprising the epithelial stem cells, or adenoma cells, and culturing the cells or fragments in the presence of a Bone Morphogenetic Protein (BMP) inhibitor, a mitogenic growth factor, and a Wnt agonist when culturing epithelial stem cells and isolated tissue fragments. The invention further relates to a cell culture medium comprising a BMP inhibitor, a mitogenic growth factor, and a Wnt agonist, to the use of the culture medium, and to crypt-villus organoids, gastric organoids, pancreatic organoids, liver organoids, colon organoids, Barrett's Esophagus organoids, adenocarcinoma organoids and colon carcinoma organoids that are formed in the culture medium.Type: ApplicationFiled: July 29, 2011Publication date: August 2, 2012Inventors: Toshiro Sato, Johannes C. Clevers, Meritxell Huch Ortega
-
Patent number: 8232101Abstract: Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia, and reduced immune function. The identification of MHC Class I, HLA-A2, associated peptides presented on multiple myeloma cells is an important step in developing immunotherapies for MM. Presented here are methods for creating activated T lymphocytes that are cytotoxic to both peptide loaded T2 target cells and multiple myeloma cell lines.Type: GrantFiled: October 31, 2011Date of Patent: July 31, 2012Assignee: Janssen Pharmaceutica N.V.Inventors: Zeling Cai, Wei-Xing Shi, Xuejun P. Liu, Jiejun Wu
-
Patent number: 8227246Abstract: This invention provides an isolated disc stem cell population, compositions, and methods of obtaining and growing the same. Moreover, this invention provides an isolated discosphere, compositions, and methods of obtaining and growing the same. An artificial disc containing the cells of the present invention is provided together with methods of making the same. This invention also provides a method of treating a subject having a herniated disc utilizing the cells and methods of the invention.Type: GrantFiled: July 7, 2008Date of Patent: July 24, 2012Assignee: DiscgenicsInventors: Valery Kukekeov, Christopher Duntsch, Tatyana Igantova
-
Patent number: 8222034Abstract: The present invention is of methods of establishing and propagating human embryonic stem cell lines using feeder cells-free, xeno-free culture systems and stem cells which are capable of being maintained in an undifferentiated, pluripotent and proliferative state in culture which is free of xeno contaminants and feeder cells.Type: GrantFiled: April 11, 2011Date of Patent: July 17, 2012Assignee: Technion Research & Development Foundation Ltd.Inventors: Michal Amit, Joseph Itskovitz-Eldor
-
Publication number: 20120178166Abstract: Fully defined media that support pluripotent cell viability, proliferation, cloning, and derivation, as well as methods and compositions including these media are described. Methods for deriving iPS cells from adult individuals under defined, xeno-free conditions are also described.Type: ApplicationFiled: December 30, 2011Publication date: July 12, 2012Inventors: Guokai Chen, James A. Thomson
-
Publication number: 20120171766Abstract: The present invention relates to a medium composition comprising neuropeptide Y, effective for proliferation and maintenance of undifferentiated pluripotent stem cells, and a method for culturing undifferentiated pluripotent stem cells using the same. The present invention improves the culture conditions for undifferentiated pluripotent stem cells, and ultimately, the present invention can be effectively used for the development of large-scale culture systems, thereby acquiring clinically applicable pluripotent stem cells. Further, the present invention relates to a dedifferentiation medium composition comprising neuropeptide Y (NPY), and a method for inducing dedifferentiation (or reprogramming) using the same. The present invention improves the culture conditions for dedifferentiation and contributes to develop technology of producing clinically applicable induced pluripotent stem cells, thereby being used for the development of stem cell therapy.Type: ApplicationFiled: June 16, 2010Publication date: July 5, 2012Inventors: Yee Sook Cho, Mi-Young Son
-
Patent number: 8211699Abstract: The present invention relates to cell culture methods and compositions that are essentially serum-free and comprise a basal salt nutrient solution and an ErbB3 ligand.Type: GrantFiled: August 13, 2007Date of Patent: July 3, 2012Assignee: ViaCyte, Inc.Inventors: Allan J. Robins, Thomas C. Schulz
-
Patent number: 8206980Abstract: A method for culture of hair follicular dermal sheath cells or precursor cells thereof which are potent cellular materials for such as hair regeneration by cell transplantation is provided. That is, by performing culture in an animal cell culture medium supplemented with platelet-derived growth factor AA (PDGF-AA) and fibroblast growth factor 2 (FGF2), hair follicular dermal sheath cells are proliferated while sustaining their function, or hair follicular dermal sheath precursor cells are differentiated into dermal sheath cells and proliferated.Type: GrantFiled: October 2, 2006Date of Patent: June 26, 2012Assignees: Phoenixbio Co., Ltd., Biointegrence Inc.Inventors: Koei Toyoshima, Mikaru Matsunaga, Katsutoshi Yoshizato
-
Publication number: 20120156782Abstract: The present disclosure related to isolated laminin-521, methods for making recombinant laminin-521, host cells that express recombinant laminin-521, and compositions containing laminin-521. Laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells. When pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency. It has also been discovered that human recombinant laminin-521 (laminin-11) provides single cell survival of stem cells after complete dissociation into a single cell suspension. Useful cell culture mediums containing at most 3.9 ng/ml of beta fibroblast growth factor (bFGF) are also described herein.Type: ApplicationFiled: December 16, 2011Publication date: June 21, 2012Applicant: BioLamina ABInventors: Karl Tryggvason, Sergey Rodin
-
Patent number: 8192951Abstract: An improved system for large scale production of proteins and/or polypeptides in cell culture is provided. In accordance with the present invention, cells expressing the protein or polypeptide of interest are grown in media that comprise a glycolysis-inhibiting substance. Additionally and/or alternatively, cells expressing the protein or polypeptide of interest are grown in media in which glutamine is limited. The use of such a system allows high levels of protein or polypeptide production and lessens accumulation of undesirable metabolic waste products such as lactate. Proteins and polypeptides expressed in accordance with the present invention may be advantageously used in the preparation of pharmaceutical, immunogenic, agricultural or other commercial compositions.Type: GrantFiled: November 2, 2007Date of Patent: June 5, 2012Assignee: Wyeth LLCInventors: Wenge Wang, Yen Tung Luan